 |
|
|
Gemeprost
|
|
| Systematic (IUPAC) name | |
| methyl (2E,11α,13E,15R)-11,15-dihydroxy-16,16-dimethyl-9-oxoprosta-2,13-dien-1-oate | |
| Identifiers | |
| CAS number | 64318-79-2 |
| ATC code | G02AD03 |
| PubChem | 5282237 |
| Chemical data | |
| Formula | C23H38O5 |
| Mol. mass | 394.545 g/mol |
| SMILES | eMolecules & PubChem |
| Synonyms | methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Pessary |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
Clinical use
It is used as a treatment for obstetric bleeding.
It is used with RU486 to terminate pregnancy up to 24 weeks gestation. [1]
Side effects
Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.
References
- ^ Bartley J, Brown A, Elton R, Baird DT (October 2001). "Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation". Human reproduction (Oxford, England) 16 (10): 2098–102. PMID 11574498. http://humrep.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=11574498. Retrieved 2008-10-29.
|
||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
